Full Press Release Details
Nuwellis, Inc. Announces First Quarter 2023 Financial Results
Minneapolis, MN, May 9, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid
overload, today reported financial results for the first quarter ended March 31, 2023.
"With growth in our heart failure segment fueled by new clinical evidence, and an active pipeline of business development activities, our team is excited
to continue executing on our growth agenda, utilizing our growing body of clinical evidence that supports use of the Aquadex ultrafiltration therapy as a mechanical fluid removal solution for fluid-overloaded patients across multiple hospital
specialty units. We remain committed to making Aquadex the standard of care for patients with fluid overload who are not responsive to conventional diuretics, and we look forward to increased sales momentum as we continue to build awareness and
drive market penetration," said Nestor Jaramillo, Jr., President & CEO of Nuwellis.
First Quarter 2023 Financial Results
Revenue for the first quarter of 2023 was $1.8 million, compared to $1.9 million in the prior-year period.
Gross margin was 58.4% for the first quarter of 2023, compared to 57.2% in the prior-year period, an increase of 120 basis points, driven primarily by
pricing increases that were effective in the second quarter of 2022.
Selling, general and administrative expenses for the first quarter of 2023 were $5.5 million, compared to $4.4 million in the prior-year period. The
increase was primarily due to increased professional fees associated with strategic initiatives and increased audit and legal expenses.
First quarter research and development expenses were $1.4 million, compared to $1.1 million in the first quarter of 2022, reflecting increased product development
costs related to the ongoing development of the Company's dedicated pediatric device.
Net loss for the first quarter of 2023 was $6.5 million, or a loss of $5.76 per basic and diluted common share, compared to a net loss of $4.5 million, or a loss of
$42.45 per basic and diluted common share, in the prior-year period. The current period loss includes a non-recurring, non-cash expense of approximately $755,000 related to the
revaluation of the warrant liability associated with the Company's October 2022 financing.
At March 31, 2023, the Company had cash, cash equivalents, and marketable securities of approximately $12.1 million and no debt, with approximately 1.2
million common shares outstanding.
Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial
results and provide an update on the Company's performance.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live
conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10177112. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming
the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis,
with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and
smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg. or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2023 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on
current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation,
those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described
in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events
PART I-FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31, 2023 | December 31, 2022 | |||||||
| ASSETS | (unaudited) | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 11,515 | $ | 17,737 | ||||
| Marketable securities | 575 | 569 | ||||||
| Accounts receivable | 1,301 | 1,406 | ||||||
| Inventories, net | 2,742 | 2,661 | ||||||
| Other current assets | 477 | 396 | ||||||
| Total current assets | 16,610 | 22,769 | ||||||
| Property, plant and equipment, net | 907 | 980 | ||||||
| Operating lease right-of-use asset | 856 | 903 | ||||||
| Other assets | 106 | 21 | ||||||
| TOTAL ASSETS | $ | 18,479 | $ | 24,673 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 2,524 | $ | 2,245 | ||||
| Accrued compensation | 1,312 | 2,161 | ||||||
| Current portion of operating lease liability | 201 | 196 | ||||||
| Current portion of finance lease liability | 21 | 28 | ||||||
| Other current liabilities | 49 | 58 | ||||||
| Total current liabilities | 4,107 | 4,688 | ||||||
| Common stock warrant liability | - | 6,868 | ||||||
| Operating lease liability | 708 | 760 | ||||||
| Total liabilities | 4,815 | 12,316 | ||||||
| Commitments and contingencies | ||||||||
| - | - | |||||||
| Stockholders' equity | ||||||||
| Series A junior participating preferred stock as of March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 30,000 shares, none outstanding | - | - | ||||||
| Series F convertible preferred stock as of both March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares | - | - | ||||||
| Series I convertible preferred stock as of March 31, 2023 and December 31, 2022, par value $0.0001; authorized 1,049,280, issued and outstanding none and 1,049,280, respectively | ||||||||
| Preferred stock as of both March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding | - | - | ||||||
| Common stock as of March 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,206,932 and 536,394 shares, respectively | - | - | ||||||
| Additional paid-in capital | 287,529 | 279,736 | ||||||
| Accumulated other comprehensive income: | ||||||||
| Foreign currency translation adjustment | (25 | ) | (18 | ) | ||||
| Unrealized gain on marketable securities | 62 | 56 | ||||||
| Accumulated deficit | (273,902 | ) | (267,417 | ) | ||||
| Total stockholders' equity | 13,664 | 12,357 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 18,479 | $ | 24,673 |
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Net sales | $ | 1,826 | $ | 1,926 | ||||
| Cost of goods sold | 759 | 824 | ||||||
| Gross profit | 1,067 | 1,102 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 5,490 | 4,412 | ||||||
| Research and development | 1,428 | 1,106 | ||||||
| Total operating expenses | 6,918 | 5,518 | ||||||
| Loss from operations | (5,851 | ) | (4,416 | ) | ||||
| Other income (expense), net | 123 | (55 | ) | |||||
| Change in fair value of warrant liability | (755 | ) | - | |||||
| Loss before income taxes | (6,483 | ) | (4,471 | ) | ||||
| Income tax expense | (2 | ) | (2 | ) | ||||
| Net loss | $ | (6,485 | ) | $ | (4,473 | ) | ||
| Basic and diluted loss per share | $ | (5.76 | ) | $ | (42.45 | ) | ||
| Weighted average shares outstanding - basic and diluted | 1,126 | 105 | ||||||
| Other comprehensive loss: | ||||||||
| Unrealized gain on marketable securities | 6 | - | ||||||
| Unrealized foreign currency translation adjustments | $ | (7 | ) | $ | (2 | ) | ||
| Total comprehensive loss | $ | (6,486 | ) | $ | (4,475 | ) |
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows
| Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (6,485 | ) | $ | (4,473 | ) | ||
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
| Depreciation and amortization | 86 | 105 | ||||||
| Stock-based compensation expense, net | 181 | 241 | ||||||
| Change in fair value of warrant liability | 755 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 105 | (201 | ) | |||||
| Inventory, net | (81 | ) | (451 | ) | ||||
| Other current assets | (81 | ) | (22 | ) | ||||
| Other assets and liabilities | (16 | ) | (80 | ) | ||||
| Accounts payable and accrued expenses | (570 | ) | 54 | |||||
| Net cash used in operating activities | (6,106 | ) | (4,827 | ) | ||||
| Investing Activities: | ||||||||
| Additions to intangible assets | (85 | ) | - | |||||
| Purchases of property and equipment | (13 | ) | (70 | ) | ||||
| Net cash used in investing activities | (98 | ) | (70 | ) | ||||
| Financing Activities: | ||||||||
| Issuance costs related to 2022 common stock offering | (11 | ) | - | |||||
| Payments on finance lease liability | - | (6 | ) | |||||
| Net cash used in financing activities | (11 | ) | (6 | ) | ||||
| Effect of exchange rate changes on cash | (7 | ) | (2 | ) | ||||
| Net decrease in cash and cash equivalents | (6,222 | ) | (4,905 | ) | ||||
| Cash and cash equivalents - beginning of period | 17,737 | 24,205 | ||||||
| Cash and cash equivalents - end of period | $ | 11,515 | $ | 19,300 |